Off-label use of cheaper Avastin in AMD in line for official blessing in France
This article was originally published in SRA
Executive Summary
The French health authorities are taking steps to implement a new legislative provision that would allow Roche's anti-VEGF product Avastin (bevacizumab) to be used to treat wet age-related macular degeneration (AMD) on the grounds that it is much cheaper than Novartis' Lucentis (ranibizumab), even though Avastin is not approved for this condition.